Treatment of anaemia in the polytrauma Jehovah's Witness

Irish Medical Journal

Volumn 96, Issue 1, 2003, Pages 8-10

  Murphy, Diarmuid P ^a   O'Donnell, T ^a   McDonnell, J ^a   McElwain, J P ^a  

^a ADELAIDE AND MEATH HOSPITAL   (Ireland)

Author keywords

[No Author keywords available]

Indexed keywords

CARBON DIOXIDE; FLUOROCARBON; HEMOGLOBIN; HEMOGLOBIN DERIVATIVE; IRON DERIVATIVE; IRON DEXTRAN; IRON SACCHARATE; OXYGEN; POLYMERIZED HEMOGLOBIN; RECOMBINANT ERYTHROPOIETIN; TRANEXAMIC ACID; ANTIFIBRINOLYTIC AGENT; BLOOD SUBSTITUTE;

ALLOGENEIC HEMATOPOIETIC STEM CELL TRANSPLANTATION; ALLOGRAFT; ANEMIA; BLEEDING; BLOOD AUTOTRANSFUSION; DRUG ABSORPTION; DRUG EFFICACY; GENERAL ANESTHESIA; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HEMODILUTION; HEMOGLOBIN DETERMINATION; HUMAN; HYPOVOLEMIA; MEDICAL ETHICS; MEDICOLEGAL ASPECT; MULTIPLE TRAUMA; PATIENT POSITIONING; REGIONAL ANESTHESIA; RELIGION; REVIEW; SIDE EFFECT; SURGICAL TECHNIQUE; BLOOD; BLOOD TRANSFUSION; BODY POSTURE; ETHICS; INJURY; IRELAND; JEHOVAH'S WITNESS;

ANEMIA; ANTIFIBRINOLYTIC AGENTS; BLOOD SUBSTITUTES; BLOOD TRANSFUSION; FLUOROCARBONS; HEMODILUTION; IRELAND; JEHOVAH'S WITNESSES; PRONE POSITION; TRANEXAMIC ACID; WOUNDS AND INJURIES;

EID: 0037265908     PISSN: 03323102     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (42)

1. The Watchtower 1945: July 1: 198-200
2. The Watchtower 1991: June 15: 17-31
3. Watch Tower Bible and Tract society. Statement to the media. 2000, June : www.ajwrb.org/basics/jwpressrelease6-14-00.jpg
4. Muramoto O. Bioethical aspects of the recent changes in the policy of refusal of blood by Jehovah's Witnesses. BMJ 2001; 322: 37-41
5. Re T. All England Law Reports 1992; 4: 647-70
6. The Watchtower 2000: June 15: 29-31
7. The Watchtower 1990: June 1: 30-1
8. Benson KT. The Jehovah's Witness patient: considerations or the anaesthesiologist. Anaesth Analg 1989; 69: 647-56
9. Stehling L. Autologous Transfusion. Int Anaesthesiol Clin 1990: 28:190-6
10. The Watchtower 1989; March 1: 30-1
11. The Association of Anaesthetists of Great Britain and Ireland. Management of Anaesthesia for Jehovah's Witnesses 1999
12. The Royal College of Surgeons of England. Code of Practice for the Surgical Management of Jehovah's Witnesses 1996
13. Modig J, Karlstrom G. Intra and post-operative blood loss and haemodynamics in total hip replacement when performed under lumbar epidural versus general anaesthesia. Eur J Anaesthesiol 1987; 4: 345-355
14. Keith I. Anaesthesia and blood loss in total hip replacement. Anaesthesia 1997; 32: 444-50
15. Sculco TP, Ranawat C. The use of spinal anaesthesia for total hip replacement arthroplasty. J Bone Joint Surg 1975; 57-A (2): 173-177
16. Chin SP, Abou-Madi N, Eurin B et al. Blood loss in total hip replacement: extradural v. phenperidine analgesia. Br J Anaesth 1982; 54: 491-495
17. Modig J. Regional Anaesthesia and blood loss. Acta Anaesthesiol Scand 1988; 32 (suppl 89): 44-8
18. Thompson GE, Miller RD, Stevens WC, Murray WR. Hypotensive anaesthesia for total hip arthroplasty: a study of blood loss and organ function (brain, heart, liver and kidney). Anaesthesiology 1978; 48: 91-96
19. Vazeery AK, Lunde O. Controlled hypotension in hip surgery. Acta Orthop Scand 1979; 50: 433-441
20. Barbier-Bohm G, Desmonts JM, Couderc C et al. Comparative effects of induced hypotension and normovolaemic haemodilution on blood loss in total hip arthroplasty. Br J Anaesth 1980; 52: 1039-1043
21. Fredin H, Gustafson C, Rosberg B. Hypotensive anaesthesia, thromboprophylaxis and postoperative thromboembolism in total hip arthroplasty. Acta Anaesthesiol Scand 1984; 28: 503-507
22. Nelson CL, Bowen WS. Total hip arthroplasty in Jehovah's Witnesses without blood transfusion. J Bone Joint Surg Am. 1986 Mar; 68 (3): 350-353
23. Rab GT, Gorin LJ, Eisele JH Bilateral total hip arthroplasty in a Jehovah's Witness with chronic anaemia. Clin Orthop. 1982 Mar; (163): 134-136
24. Klein J. Normobaric pulmonary oxygen toxicity. Anaesth Analg 1990; 70: 195-207
25. Borghi B, Bassi A, De Simone N et al, Autotransfusion: 15 years experience at Rizzoli Orthopaedic Institute. Int J Artif Organs 1993; 16 (Suppl 5): 241-246
26. Giordano GF, Giordano DM, Wallace BA et al, An analysis of 9,918 consecutive perioperative autotransfusions. Surg Gynecol Obstet 1993: 176 (2): 103-110
27. Keeling MM, Gray LA Jr, Brink MA et al, Intraoperative autotransfusion. Experience in 725 consecutive cases. Ann Surg 1983; 197 (5): 536-541
28. Horrow JC, Hlavacek J, Strong MD et al. Prophylactic tranexamic acid decreases bleeding after cardiac operations. J Thorac Cardiovasc Surg 1990; 99: 70-74
29. Karski JM, Teasdale SJ, Norman PH et al. Prevention of postbypass bleeding with tranexamic acid and e-aminocaproic acid. J Cardiothorac Vasc Anesth 1993; 41: 473-435
30. Roussou JA, Engelman RM, Flack JE et al, Tranexamic acid significantly reduces blood loss associated with coronary revascularisation. Ann Thorac Surg 1995; 59: 671-675
31. Geisser P, Baer M, Schaub E. Structure/histotoxicity relationship of parenteral iron preparations. Arzneimitteelforschung 1992; 42: 1439-1452
32. Sparling EA, Nelson CL, Lavender R, Smith J. The use of erythropoietin in the management of Jehovah's Witnesses who have revision total hip arthroplasty. J Bone Joint Surg Am 1996 Oct; 78(10): 1548-1552
33. Gaudiani VA, Mason DW, Preoperative erythropoietin in Jehovah's Witnesses who require cardiac procedures. Ann Thorac Surg 1991; 51: 823-824
34. Koenig HM, Levine EA, Resnick DJ, Meyer WJ. Use of recombinant human erythropoietin in a Jehovah's Witness. J Clin Anesth 1993; 5: 244-247
35. Fullerton DA, Cambell DN, Whitman G Jr. Use of human recombinant erythropoietin to correct severe preoperative anaemia. Ann Thorac Surg 1991; 51: 825-826
36. Connor JP, Olsson CA. The use of recombinant human erythropoietin in a Jehovah's Witness requiring major reconstructive surgery. J Urol 1992; 147: 131-132
37. Mudd S, Thalhimer W. Blood substitutes and blood transfusion. Baltimore: Charles Thomas Books, 1942:156
38. Mullon J, Giacoppe G, et al. Transfusion of Polymerized Bovine Hemoglobin in a Patient with Severe Autoimmune Haemolytic Anemia. NEJM 2000 342; 22 : 1638-1643
39. Bailey R Ariga T. the view of Jehovah's witnesses on blood s substitutes. Artif Cells Blood substit Immobil Biotechnol 1998; 26: 571-6
40. Reiss JG. The design and development of improved flurocarbon-based products for use in medicine and biology. Art Cells, Blood Subs, Immob Biotech 1994; 22: 215-234
41. Kaufman JR. Clinical development of perflurocarbon-based emulsions as red cell substitutes. In: Winslow RM, Vandegriff KD, Intaglietta M, eds. Blood substitutes: physiological basis of efficacy. Boston: Birkhauser, 1995: 53-74
42. Spence RK, Norcross ED, Costabile J et al. Perflurocarbons as blood substitutes: the early years. Experience with Fluosol DA- 20% in the 1980s.